Next-generation cell line development platform for advanced bispecific antibodies expression
A bispecific monoclonal antibody (bsAbs), or multispecific antibody, can simultaneously bind to two or more different types of antigen. Bispecifics can be manufactured in several structural formats, and current applications have been explored for cancer immunotherapy and drug delivery. The promise of bispecifics comes from their ability to behave like a cellular therapy, even though they are an “off-the-shelf” product. An “off-the-shelf” therapy, rather than one that needs to be manufactured individually for each patient (such as chimeric antigen receptor T (CAR-T) cell therapies), can be a life-saving proposition for patients facing difficult-to-treat and rapidly progressing disease, such as many cancers.
In our webinar “Next-generation cell line development platform for advanced bispecific antibodies expression,” we will address the key challenges of expressing bispecifics in Chinese hamster ovary (CHO) cells.
ABOUT THE SPEAKER
VP, Cell Line Development Services
Séverine joined Selexis in December 2015 to lead the Cell Line Development, the Bioprocess and the Analytics Departments. In her role, she ensures the continuous generation of high-performance stable cell lines, including recombinant protein characterization. Séverine also works on providing scale-down bioreactor data using Ambr® 15 to facilitate the transfer to CMOs. Séverine earned her PhD in protein engineering from a private company, Novimmune, where she focused on the generation of broad-spectrum chemokine inhibitors by using directed mutagenesis, phage display isolation, functional characterization and epitope mapping. She subsequently held a postdoctoral position at the University of Geneva (CH, Prof. Hartley’s group) where she designed a novel phage display platform for accelerating bispecific antibody development.
Cell Line Development Partner of Choice
Selexis SA, A JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
Selexis SUREtechnology Platform™
Our global partners are utilizing Selexis gene technologies to advance more than 130 drug products in clinical development and the manufacture of seven commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.